Discovered by Takeda, Blopress is an angiotensin receptor blocker (ARB) which inhibits action of a vasopressor hormone, angiotensin II. In Japan, it was launched in 1999 and was the first ARB to obtain an additional indication for chronic heart failure in 2005, said Takeda.
Amlodipine besylate is a calcium channel blocker, having a hypotensive action by blocking inward calcium ion channels mainly in vascular smooth-muscle cells, resulting in peripheral arteriolar vasodilation.
If approved, Takeda expects that the combination of Blopress and amlodipine besylate can offer a new treatment option for those who are currently taking both medicines and also those who are taking either one of two medicines as monotherapy but needing additional treatment.